Business, energy, technology, markets and global industry news from Business News Today

BRAFTOVI

PharmaDeviceNews BRAFTOVI
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Pharma & Biotech

Pfizer’s BRAFTOVI triplet shows 64% response in first-line BRAF-mutant colorectal cancer

Pfizer’s BRAFTOVI triplet hit a 64% response rate in BRAF-mutant colorectal cancer. Find out what this could mean for first-line treatment standards.

Read More